Efficacy and Safety of Oral Treprostinil Monotherapy for the Treatment of Pulmonary Arterial Hypertension
Authors:
- Zhi-Cheng JingZJZhi-Cheng Jing
- Keyur ParikhKPKeyur Parikh
- Tomas PulidoTPTomas Pulido
- Carlos Jerjes-SanchezCJCarlos Jerjes-Sanchez
- R. James WhiteRWR. James White
- Roblee AllenRARoblee Allen
- Adam TorbickiATAdam Torbicki
- Kai-Feng XuKXKai-Feng Xu
- David YehleDYDavid Yehle
- Kevin LaliberteKLKevin Laliberte
- Carl ArnesonCACarl Arneson
- Lewis J. RubinLRLewis J. Rubin
- 5 February 2013
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 127 (5) , 624-633
Abstract
Background—: Pulmonary arterial hypertension (PAH) is a progressive, fatal disease with no cure. Parenteral and inhaled prostacyclin analogue therapies are effective for the treatment of PAH, but complicated administration requirements can limit the use of these therapies in patients with less severe disease. This study was designed to evaluate the safety and efficacy of the oral prostacyclin analogue treprostinil diolamine as initial treatment for de novo PAH. Methods and Results—: Three hundred forty-nine patients (intent-to-treat population) not receiving endothelin receptor antagonist or phosphodiesterase type-5 inhibitor background therapy were randomized (treprostinil, n=233; placebo, n=116). The primary analysis population (modified intent-to-treat) included 228 patients (treprostinil, n=151; placebo, n=77) with access to 0.25-mg treprostinil tablets at randomization. The primary end point was change from baseline in 6-minute walk distance at week 12. Secondary end points included Borg dyspnea index, clinical worsening, and symptoms of PAH. The week 12 treatment effect for 6-minute walk distance (modified intent-to-treat population) was 23.0 m ( P =0.0125). For the intent-to-treat population, 6-minute walk distance improvements were observed at peak (26.0 m; P =0.0001) and trough (17.0 m; P =0.0025) plasma study drug concentrations. Other than an improvement in the combined 6-minute walk distance/Borg dyspnea score, there were no significant changes in secondary end points. Oral treprostinil therapy was generally well tolerated; the most common adverse events (intent-to-treat) were headache (69%), nausea (39%), diarrhea (37%), and pain in jaw (25%). Conclusions—: Oral treprostinil improves exercise capacity in PAH patients not receiving other treatment. Oral treprostinil could provide a convenient, first-line prostacyclin treatment option for PAH patients not requiring more intensive therapy. Clinical Trial Registration:—: URL: http://www.clinicaltrials.gov . Unique identifier: NCT00325403 .Keywords
This publication has 31 references indexed in Scilit:
- Inhaled treprostinil: a therapeutic reviewDrug Design, Development and Therapy, 2012
- Addition of Inhaled Treprostinil to Oral Therapy for Pulmonary Arterial HypertensionJACC, 2010
- Tadalafil Therapy for Pulmonary Arterial HypertensionCirculation, 2009
- Ambrisentan for the Treatment of Pulmonary Arterial HypertensionCirculation, 2008
- Dose Proportionality of Treprostinil Sodium Administered by Continuous Subcutaneous and Intravenous InfusionThe Journal of Clinical Pharmacology, 2008
- Safety and Efficacy of Inhaled Treprostinil as Add-On Therapy to Bosentan in Pulmonary Arterial HypertensionJACC, 2006
- Sildenafil Citrate Therapy for Pulmonary Arterial HypertensionNew England Journal of Medicine, 2005
- Treatment of Pulmonary Arterial HypertensionNew England Journal of Medicine, 2004
- Inhaled Iloprost for Severe Pulmonary HypertensionNew England Journal of Medicine, 2002
- A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary HypertensionNew England Journal of Medicine, 1996